Mario Schlosser, serving as a director at Oscar Health, Inc. (NASDAQ:OSCR), completed a substantial divestiture of company equity on June 23, 2026. The director offloaded a total of 1,026,500 shares of Oscar Health’s Class A Common Stock, realizing proceeds of approximately $30.18 million. These shares were transacted at prices fluctuating between $28.08 and $30.09 per share. The execution of these sales occurs as Oscar Health shares hover near their 52-week peak of $30.38, a level reached following a notable 95% appreciation over the previous six-month period. Despite this recent rally, valuation metrics suggest the stock remains slightly undervalued relative to its Fair Value, positioning it within lists of undervalued opportunities.
The sales were structured under a Rule 10b5-1 trading plan, a mechanism designed to allow insiders to establish predetermined schedules for buying or selling shares. This framework helps mitigate accusations of trading based on material non-public information. Mr. Schlosser directly sold 879,000 shares of Class A Common Stock. These direct transactions occurred at weighted average prices of $28.95 for 286,988 shares (ranging from $28.08 to $29.07), $29.58 for 591,213 shares (ranging from $29.08 to $30.04), and $30.09 for 1,799 shares.
In addition to direct sales, shares were disposed of indirectly through three family trusts. The Noah Pizzo-Schlosser Dynasty Trust sold 50,000 shares, the Siena Pizzo-Schlosser Dynasty Trust sold 50,000 shares, and the Pizzo-Schlosser Family Dynasty Trust sold 47,500 shares. These indirect sales were executed at weighted average prices of $28.95, $29.58, and $30.09, mirroring the direct sale price points. Mr. Schlosser disclaims beneficial ownership over the shares held by these trusts, except to the extent of his pecuniary interest therein, if any.
On the same date, Mr. Schlosser also acquired 1,027,500 shares of Class A Common Stock through the conversion of Class B Common Stock. This acquisition included 660,000 shares obtained from the exercise of a stock option at an exercise price of $9.75 per share. The Class B common stock is convertible into Class A common stock on a one-to-one basis. Following these transactions, Mr. Schlosser directly held 480,866 shares of Class A Common Stock. The three family trusts held 0 shares of Class A Common Stock after their respective sales. Mr. Schlosser also held derivative securities in the form of Class B Common Stock convertible to Class A.
Recent market developments for Oscar Health include notable analyst actions. Barclays upgraded Oscar Health to Overweight from Equalweight, raising its price target to $35.00, citing potential for a multi-year re-rating and margin recovery. Wells Fargo also upgraded the company to Equal Weight from Underweight, with a new price target of $20.00, reflecting increased confidence in the exchange market trajectory for 2026. Meanwhile, Raymond James reiterated an Outperform rating, maintaining a $30.00 price target following a federal judge’s decision on marketplace regulations.
Options trading activity for Oscar Health surged to 52,384 contracts, with call options significantly outnumbering puts. The company also announced changes to Mr. Schlosser’s role, transitioning him to Co-Founder & Advisor to the CEO while he continues to support AI and digital health initiatives. These updates reflect ongoing strategic adjustments and market reactions surrounding Oscar Health.